19,613 Shares in Halozyme Therapeutics, Inc. $HALO Acquired by RFG Advisory LLC

RFG Advisory LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 19,613 shares of the biopharmaceutical company’s stock, valued at approximately $1,535,000.

Other large investors have also recently modified their holdings of the company. MidFirst Bank acquired a new position in shares of Halozyme Therapeutics during the second quarter worth $27,000. Larson Financial Group LLC raised its position in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Halozyme Therapeutics during the 2nd quarter worth about $28,000. Measured Wealth Private Client Group LLC grew its position in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $30,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $107.20 on Friday. The business has a 50-day simple moving average of $93.73 and a 200 day simple moving average of $76.97. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $111.15. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The firm has a market capitalization of $12.17 billion, a price-to-earnings ratio of 32.00, a PEG ratio of 0.41 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same quarter in the prior year, the company earned $1.54 earnings per share. The company’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. This trade represents a 33.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $82,482,605.40. The trade was a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 72,478 shares of company stock valued at $7,370,004 over the last ninety days. 2.50% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on HALO. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Citizens Jmp boosted their price target on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. HC Wainwright reiterated a “buy” rating and set a $115.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, September 2nd. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $91.20.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.